Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?

Abstract

Objective: Since the clinical symptoms of different types of dementia frequently overlap, especially in the earlier stages at onset, it is difficult to distinguish dementia with Lewy bodies (DLB) from other neurodegenerative dementias based on their clinical manifestations alone. Nuclear medicine imaging has been reported as a high-value index for the objective evaluation and diagnosis of DLB. The aim of this study was to evaluate whether nuclear medicine imaging findings may yield core features to be added to the diagnosis of DLB. Methods: We enrolled 332 patients with suspected DLB. All were evaluated by both 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy and 123I-labelled N-isopropyl-p-iodoamphetamine (123I-IMP). brain perfusion single-photon emission CT. The final clinical diagnosis indicated probable DLB in 92 patients (40 males, 52 females; mean age ± standard deviation, 77.4 ± 6.4 years; range, 56–89 years); 240 patients (98 males, 142 females; mean age, 75.5 ± 9.0 years; range, 70–87 years) were recorded as being without DLB. The accepted core features used for clinical evaluations were fluctuating cognition, visual hallucinations and Parkinsonism. The nuclear medicine evaluation indices were the severity score of cerebral blood flow on 123I-IMP scintigraphs of the posterior cingulate and praecuneus and a reduction in the blood flow in the occipital lobe. For 123I-MIBG evaluation, we recorded the early and delayed heart-to-mediastinum (H/M) ratios and the washout rate. Results: Univariate and multivariate analyses of fluctuating cognition, visual hallucinations, Parkinsonism and early H/M ratio in patients with probable and without DLB revealed significant differences. Parameters based on 123I-IMP studies did not show any significant differences by multivariate analysis. The area under the curve for the early H/M ratio was 0.918; for fluctuating cognition, visual hallucinations and Parkinsonism, it was 0.693, 0.760 and 0.611, respectively, by receiver-operating characteristic analysis. The early H/M ratio of <2.0 on 123I-MIBG scintigraphs was of the highest diagnostic accuracy. The sensitivity, specificity and accuracy for the diagnosis of probable DLB were 82.4%, 96.3% and 92.5%, respectively. Conclusion: The early H/M ratio obtained by 123I-MIBG myocardial scintigraphy can serve as a reliable diagnostic index for the core clinical features of DLB. It can be used for the early diagnosis and treatment of DLB. Advances in knowledge: 123I-MIBG myocardial scintigraphy performed at the initial clinical examination can facilitate the early identification or exclusion of DLB and the early H/M ratio may be a diagnostic biomarker for DLB.

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes

“…The current literature on perfusion SPECT is limited by lack of pathology-confirmed investigations, small sample sizes, and a handful of studies in MSA, PSP, and CBS. Moreover, given the overlap in perfusion profiles, other techniques (e.g., 123 I-metaiodobenzylguanidine myocardial scintigraphy or DAT imaging) may perform superior to perfusion SPECT in some cases ( 258 ). Multimodal imaging can provide valuable diagnostic information in uncertain cases ( 10 ).…”

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

“…SPECT imaging using 123 I–metaiodobenzylguanidine, a marker of postganglionic sympathetic innervation, showed reduced cardiac uptake in both DLB and PDD as compared with AD [ 110 , 111 ]. The sensitivity, specificity, and accuracy for the diagnosis of probable DLB is 82.4%, 96.3%, and 92.5%, respectively [ 112 ]; yet, although specific data on PDD are not available, 123 I–metaiodobenzylguanidine imaging is unlikely to differentiate PDD from DLB.…”

The role of molecular imaging in the frame of the revised dementia with Lewy body criteria

“…However, increasing evidence clearly showed that the approach of moving mainly from the clinical features as markers of disease presented with several limitations [5]. Indeed, clinical core symptoms were reported to appear relatively late in the course of the disease and to overlap with clinical symptoms of other dementing diseases, especially in the earlier stage, thus making difficult to distinguish DLB from other neurodegenerative dementias based on clinical manifestations alone [6]. On the other hand, results of epidemiologic and clinical studies showed that DLB is the second commonest cause of neurodegenerative dementia, and that it progresses more rapidly than other dementing disorders, harboring a poor prognosis due to severe cognitive impairment and parkinsonism [7].…”